The Honest Company: The Turnaround Is Real, But I'm Not Chasing The Rally
The Honest Company has executed a successful turnaround, driving margin expansion and profitability through strategic exits and cost reductions. HNST's core product lines—wipes and personal care—are now 70% of consumption and are fueling organic growth, offsetting diaper segment declines. Management raised 2026 guidance: $319–$325M revenue, 5–7% organic growth, mid-40% gross margins, and $23–$25M EBITDA.
The Honest Company: Strategic Exits Are Starting To Work
The Honest Company: Strategic Exits Are Starting To Work
The Honest Company - Awaiting More Consistent Improvements
The Honest Company faces stagnating improvements, with shares down 25% over the past year and operating profits still elusive. Despite organic growth, Honest's top-line sales are declining due to divestitures, and adjusted EBITDA margins have contracted year-over-year. Guidance for 2026 anticipates further sales declines but expects organic growth and flat adjusted EBITDA, with continued net cash strength.
The Honest Company, Inc. (HNST) Q2 2026 Earnings Call Transcript
The Honest Company, Inc. (HNST) Q2 2026 Earnings Call Transcript
Honest Q2 Earnings Call Highlights
Honest NASDAQ: HNST reported second-quarter results marked by organic revenue growth, record underlying profitability and stronger consumption trends in its Wipes and Personal Care businesses, while reported revenue declined due to strategic exits and continued pressure in diapers.
Honest (HNST) Q2 Earnings and Revenues Beat Estimates
Honest (HNST) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.03 per share a year ago.
How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take.
Bristol Myers Squibb's yield is well above the pharma average, and it has patent expirations on the horizon. The payout ratio isn't outlandishly high, and the company is financially strong, as it deals with pretty normal issues in the drug sector.
Surging Earnings Estimates Signal Upside for Honest (HNST) Stock
Honest (HNST) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
The Honest Company: 3 Year Update With A 'Hold' But Increased Price Target
The Honest Company remains rated 'Hold' with a new $2.21/share price target, reflecting improved fundamentals but insufficient risk-adjusted upside. HNST has transitioned from digital to retail channels, exited low-margin categories, and achieved significant gross margin expansion to 43.5%. The company is now debt-free, generating positive free cash flow and adjusted EBITDA, with organic growth expected to normalize at 4-6%.
The Honest Company, Inc. (HNST) Q1 2026 Earnings Call Transcript
The Honest Company, Inc. (HNST) Q1 2026 Earnings Call Transcript
Honest (HNST) Q1 Earnings Meet Estimates
Honest (HNST) came out with quarterly earnings of $0.01 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.03 per share a year ago.
The Honest Company: Strong Cash Position As Transformation Gains Traction
The Honest Company delivered Q4 2025 results showing enhanced cash levels and a strong, debt-free balance sheet despite ongoing transformation. HNST announced its first $25 million share repurchase program, signaling management's confidence in the company's future prospects. HNST trades at a low 0.57x forward EV/Sales, with margin expansion positioning it for potential rerating.
